ReviewStem cell research2014
Cardiac regeneration using pluripotent stem cells--progression to large animal models.
Review in Stem cell research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Preclinical Large AnimalCurrent cardiology reviews · 2023Pooled it
- Melt electrowritten medium chain length polyhydroxyalkanoate cardiac patches for Post-MI cardiac regeneration.Materials today. Bio · 2025Article
- Spaceflight alters protein levels and gene expression associated with stress response and metabolic characteristics in human cardiac spheroids.Biomaterials · 2025Article
- Trials and tribulations of cell therapy for heart failure: an update on ongoing trials.Nature reviews. Cardiology · 2025Review
- The importance of matrix in cardiomyogenesis: Defined substrates for maturation and chamber specificity.Matrix biology plus · 2024Article
- Simulated microgravity improves maturation of cardiomyocytes derived from human induced pluripotent stem cells.Scientific reports · 2024Article
- Non-human primate studies for cardiomyocyte transplantation-ready for translation?Frontiers in pharmacology · 2024Review
- Cell Therapy in the Treatment of Coronary Heart Disease.International journal of molecular sciences · 2023Review
- Review
- Whole-Heart Tissue Engineering and Cardiac Patches: Challenges and Promises.Bioengineering (Basel, Switzerland) · 2023Review
- Space microgravity improves proliferation of human iPSC-derived cardiomyocytes.Stem cell reports · 2022Article
- Strategies for Expanding Donors Pool in Heart Transplantation.Reviews in cardiovascular medicine · 2022Review
- Is a Bioengineered Heart From Recipient Tissues the Answer to the Shortage of Donors in Heart Transplantation?Cureus · 2022Review
- The Structural and the Functional Aspects of Intercellular Communication in iPSC-Cardiomyocytes.International journal of molecular sciences · 2022Review
- Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.Cardiovascular research · 2022Review
- Porcine Organotypic Epicardial Slice Protocol: A Tool for the Study of Epicardium in Cardiovascular Research.Frontiers in cardiovascular medicine · 2022Article
- Recent progress of iPSC technology in cardiac diseases.Archives of toxicology · 2021Review
- Article
- Model Systems for Addressing Mechanism of Arrhythmogenesis in Cardiac Repair.Current cardiology reports · 2021Review
- Engineering and Assessing Cardiac Tissue Complexity.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Pluripotent stem cells (PSCs) have indisputable cardiomyogenic potential and therefore have been intensively investigated as a potential cardiac regenerative therapy. Current directed differentiation protocols are able to produce high yields of cardiomyocytes from PSCs and studies in small animal models of cardiovascular disease have proven sustained engraftment and functional efficacy. Therefore, the time is ripe for cardiac regenerative therapies using PSC derivatives to be tested in large animal models that more closely resemble the hearts of humans. In this review, we discuss the results of our recent study using human embryonic stem cell derived cardiomyocytes (hESC-CM) in a non-human primate model of ischemic cardiac injury. Large scale remuscularization, electromechanical coupling and short-term arrhythmias demonstrated by our hESC-CM grafts are discussed in the context of other studies using adult stem cells for cardiac regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.